Tat-TAR Complex Binding Compounds for HIV Latency Reactivation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current latency-reversing agents (LRAs) for HIV-1 are ineffective in significantly reducing the viral reservoir in patients, as they target cellular proteins and have side effects that inhibit cytotoxic function, failing to effectively reactivate latent HIV-infected cells.
Innovation Solution
Development of compounds that target the Tat protein of HIV, specifically binding to the Tat-TAR transcription complex to promote transcriptional activity, thereby lifting HIV latency in infected cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If latency-reversing agents target cellular proteins to reactivate HIV, then viral reactivation occurs, but cytotoxic function of CD8 cells is inhibited
Solution Approach 1:
The patent introduces a small molecule compound as an intermediary that specifically binds to the Tat-TAR complex to modulate its activity. This intermediary approach allows selective reactivation of latent HIV through the Tat-TAR pathway without affecting cellular proteins like HDACs or PKC, thereby avoiding inhibition of CD8 cell cytotoxic function while achieving viral reactivation
Solution Approach 2:
The invention changes the molecular target parameter from cellular proteins to viral protein complexes (Tat-TAR). By shifting the target from host cell components to viral-specific components, the treatment achieves viral reactivation while preserving host immune cell function, as the viral Tat-TAR complex is unique to HIV and not involved in normal cellular processes
2Reliability
If latency-reversing agents are used to activate HIV production, then latent cells can be targeted, but the viral reservoir size does not significantly decrease in patients
Solution Approach 1:
The patent applies preliminary action by first activating the Tat-TAR transcription complex to induce viral gene expression and production in latent cells. This preliminary activation step is designed to work in combination with subsequent antiviral therapies, creating a two-phase strategy where viral reactivation precedes and enables effective targeting of the viral reservoir
Solution Approach 2:
The small molecule compound targets the universal Tat-TAR mechanism that is essential for HIV replication across all latent cells. By addressing this fundamental viral transcription mechanism rather than cell-type-specific pathways, the invention achieves broad reactivation of latent HIV reservoirs regardless of the specific cell type or latency mechanism
3Quantity of substance
If antiretroviral drugs suppress HIV replication, then viral load decreases, but latent reservoirs persist and cause viral rebound
Solution Approach 1:
The patent applies inversion by reversing the conventional approach: instead of only suppressing viral replication with antiretroviral drugs, the invention actively reactivates latent virus production. This inverted strategy transforms the latent reservoir from a hidden threat into an active target, enabling subsequent elimination through immune response or combination therapies
Solution Approach 2:
The invention implements periodic action through a two-phase treatment approach: first suppressing viral replication with ART to reduce active viral load, then periodically administering Tat-TAR activators to reactivate and expose latent reservoirs. This periodic alternation between suppression and reactivation phases enables progressive reduction of the viral reservoir over time
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds effectively reactivate latent HIV-infected cells by enhancing Tat protein activity, demonstrating strong affinity for the Tat-TAR complex and promoting transcriptional activity, potentially allowing for more effective treatment of HIV by enhancing antiviral therapies.
Implementation Method 1
The compounds according to the invention have a high affinity for the Tat-TAR transcription complex, and promote the transcriptional activity of this protein, thus making it possible to lift HIV latency in HIV-infected cells
Data Source
Figure 1A~1B
Figure 2~3A
Figure 3B~4
AI summary
The present invention provides compounds capable of binding to the Tat-TAR complex in latent HIV-infected cells, so as to transactivate the Tat protein and to counteract the latency of the HIV in said cells.